Research programme: CXCR2 antagonists - Johnson & Johnson

Drug Profile

Research programme: CXCR2 antagonists - Johnson & Johnson

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Indoles; Sulfonamides; Sulfonylureas
  • Mechanism of Action Interleukin 8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Lung disorders; Respiratory tract disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (PO)
  • 20 Aug 2008 Preclinical trials in Lung disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top